Celltrion Pharm, Inc. (068760.KQ)
KRW 52700.0
(0.0%)
KRW 52700.0
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 388.79 Billion KRW | 0.71% |
| 2022 | 386.03 Billion KRW | -3.18% |
| 2021 | 398.73 Billion KRW | 70.72% |
| 2020 | 233.56 Billion KRW | 34.61% |
| 2019 | 173.51 Billion KRW | 18.13% |
| 2018 | 146.88 Billion KRW | 8.11% |
| 2017 | 135.86 Billion KRW | 29.62% |
| 2016 | 104.81 Billion KRW | 40.25% |
| 2015 | 74.73 Billion KRW | 111868.17% |
| 2014 | 66.74 Million KRW | 26.75% |
| 2013 | 52.65 Million KRW | 12.11% |
| 2012 | 46.96 Million KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 96.96 Billion KRW | 1.91% |
| 2024 Q2 | 117.15 Billion KRW | 20.82% |
| 2023 Q3 | 93.38 Billion KRW | -15.29% |
| 2023 Q4 | 95.15 Billion KRW | 1.9% |
| 2023 FY | 388.79 Billion KRW | 0.71% |
| 2023 Q1 | 90.01 Billion KRW | 2.17% |
| 2023 Q2 | 110.24 Billion KRW | 22.48% |
| 2022 FY | 386.03 Billion KRW | -3.18% |
| 2022 Q4 | 88.09 Billion KRW | -15.12% |
| 2022 Q1 | 88.75 Billion KRW | -28.16% |
| 2022 Q3 | 103.79 Billion KRW | -1.51% |
| 2022 Q2 | 105.39 Billion KRW | 18.74% |
| 2021 Q3 | 90.9 Billion KRW | -7.94% |
| 2021 Q4 | 123.54 Billion KRW | 35.91% |
| 2021 Q2 | 98.74 Billion KRW | 15.42% |
| 2021 Q1 | 85.55 Billion KRW | 110582.65% |
| 2021 FY | 398.73 Billion KRW | 70.72% |
| 2020 Q3 | 65.49 Million KRW | 41.17% |
| 2020 FY | 233.56 Billion KRW | 34.61% |
| 2020 Q4 | 77.29 Million KRW | 18.02% |
| 2020 Q2 | 46.39 Million KRW | 4.51% |
| 2020 Q1 | 44.38 Million KRW | -1.06% |
| 2019 FY | 173.51 Billion KRW | 18.13% |
| 2019 Q3 | 47.43 Million KRW | 11.3% |
| 2019 Q1 | 38.58 Million KRW | -23.62% |
| 2019 Q4 | 44.86 Million KRW | -5.42% |
| 2019 Q2 | 42.62 Million KRW | 10.45% |
| 2018 Q2 | 34.29 Million KRW | 25.54% |
| 2018 FY | 146.88 Billion KRW | 8.11% |
| 2018 Q1 | 27.32 Million KRW | -39.77% |
| 2018 Q4 | 50.52 Million KRW | 45.44% |
| 2018 Q3 | 34.73 Million KRW | 1.28% |
| 2017 Q1 | 22.16 Million KRW | -42.91% |
| 2017 Q2 | 33.84 Million KRW | 52.7% |
| 2017 FY | 135.86 Billion KRW | 29.62% |
| 2017 Q4 | 45.35 Million KRW | 31.49% |
| 2017 Q3 | 34.49 Million KRW | 1.91% |
| 2016 Q3 | 22.12 Million KRW | -14.61% |
| 2016 FY | 104.81 Billion KRW | 40.25% |
| 2016 Q1 | 17.95 Million KRW | -8.26% |
| 2016 Q2 | 25.9 Million KRW | 44.29% |
| 2016 Q4 | 38.82 Million KRW | 75.49% |
| 2015 Q3 | 19.5 Million KRW | -0.37% |
| 2015 Q2 | 19.57 Million KRW | 21.76% |
| 2015 Q1 | 16.07 Million KRW | 0.61% |
| 2015 FY | 74.73 Billion KRW | 111868.17% |
| 2015 Q4 | 19.57 Million KRW | 0.34% |
| 2014 Q3 | 20.36 Million KRW | 11.86% |
| 2014 FY | 66.74 Million KRW | 26.75% |
| 2014 Q4 | 15.98 Million KRW | -21.54% |
| 2014 Q2 | 18.2 Million KRW | 49.41% |
| 2014 Q1 | 12.18 Million KRW | -13.89% |
| 2013 Q3 | 12.81 Million KRW | 1.39% |
| 2013 FY | 52.65 Million KRW | 12.11% |
| 2013 Q1 | 13.04 Million KRW | -7.37% |
| 2013 Q4 | 14.15 Million KRW | 10.44% |
| 2013 Q2 | 12.63 Million KRW | -3.14% |
| 2012 Q4 | 14.08 Million KRW | 0.0% |
| 2012 FY | 46.96 Million KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 135.95 Billion KRW | -185.978% |
| CMG Pharmaceutical Co., Ltd. | 93.9 Billion KRW | -314.022% |
| Huons Global Co., Ltd. | 758.37 Billion KRW | 48.734% |
| DongKook Pharmaceutical Co., Ltd. | 730.99 Billion KRW | 46.813% |
| Enzychem Lifesciences Corporation | 76.03 Billion KRW | -411.31% |
| Humedix Co., Ltd. | 152.27 Billion KRW | -155.326% |
| Boditech Med Inc. | 134.21 Billion KRW | -189.671% |
| EuBiologics Co., Ltd. | 69.36 Billion KRW | -460.5% |
| FutureChem Co.,Ltd | 13.96 Billion KRW | -2683.461% |
| Huons Co., Ltd. | 552 Billion KRW | 29.567% |
| BNC Korea Co., Ltd. | 80.99 Billion KRW | -380.008% |
| AptaBio Therapeutics Inc. | 323.86 Million KRW | -119946.857% |